Nkarta, Inc.
Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.
NKTX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US65487U1088
- LEI:
- Country:
- United States of America
- Address:
- 1150 VETERANS BOULEVARD, 94080 SOUTH SAN FRANCISCO
- Website:
- https://www.nkartatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. The company focuses on treating both cancer and autoimmune diseases by harnessing the inherent power of NK cells to identify and eliminate dysfunctional or diseased cells. Founded on a proprietary and robust NK cell expansion and engineering platform, Nkarta aims to develop the next generation of cell therapies with enhanced power, applicability, and tolerability. Its technology is designed to create readily available treatments capable of reaching a broad patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Nkarta, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nkarta, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nkarta, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
